Corundum Systems Biology

Holobiome is a biotechnology company based in Cambridge, Massachusetts, focused on developing microbiome-based therapeutics for treating diseases of the enteric and central nervous systems. Established in 2015, the company aims to address mental health issues such as depression and anxiety by leveraging the gut-brain axis through next-generation probiotics. By mapping and manipulating the human gut microbiome, Holobiome provides healthcare providers with innovative interventions that enhance patient recovery and improve metabolic and immune responses, all while minimizing pain and suffering associated with these conditions.

Freya Biosciences is a clinical-stage company focused on women's health, with operations in Copenhagen and Boston. It specializes in developing microbial immunotherapies aimed at addressing significant unmet medical needs across various conditions. The company utilizes a proprietary platform to engineer and manufacture live microbes, ensuring their safety and efficacy for human use. Through this innovative approach, Freya Biosciences seeks to create new treatment options for a range of diseases, striving to make a meaningful impact in the healthcare sector.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Holobiome is a biotechnology company based in Cambridge, Massachusetts, focused on developing microbiome-based therapeutics for treating diseases of the enteric and central nervous systems. Established in 2015, the company aims to address mental health issues such as depression and anxiety by leveraging the gut-brain axis through next-generation probiotics. By mapping and manipulating the human gut microbiome, Holobiome provides healthcare providers with innovative interventions that enhance patient recovery and improve metabolic and immune responses, all while minimizing pain and suffering associated with these conditions.

Axial Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases and disorders. Based in Waltham, Massachusetts, the company utilizes a microbiome discovery platform that targets the gut-brain axis, allowing for the exploration and creation of innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Incorporated in 2013, Axial Biotherapeutics seeks to advance its pipeline of novel treatments to address the unmet needs in the field of CNS disorders.